June 13, 2026
In Vivo CAR T: A New Route to Treating Autoimmune Disease
A confluence of technological advancements enabling targeted in vivo delivery are beginning to release the brakes on the development of CAR T-cell therapies for autoimmune disease, where the patient population’s risk-benefit calculus favors interventions that are precise, reversible, and calibrated.
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments